10/54**9**871

### PATENT COOPERATION TREATY

# **PCT**

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference					
Applicant's or agent's file reference	FOR FURTHER ACTION	See Form PCT/IPEA/416			
International application No.	International filing date (day/month/year)	Priority date (day/month/year)			
PCT/EP2004/002582	12.03.2004	19.03.2003			
International Patent Classification (IPC) or r	national classification and IPC	,			
Applicant  BASF AKTIENGESELLSC	HAFT				
This report is the international pr under Article 35 and transmitted t	reliminary examination report, established by o the applicant according to Article 36.	this International Preliminary Examining Authority			
2. This REPORT consists of a total of	of 5 sheets, in	cluding this cover sheet.			
3. This report is also accompanied b	y ANNEXES, comprising:				
a. (sent to the applicant	and to the International Bureau) a total of	sheets, as follows:			
sheets of the des	erintion claims and/or drawings which have	been amended and are the basis for this report and/or see Rule 70.16 and Section 607 of the Administrative			
cheets which su	persede earlier sheets, but which this Authoria the international application as filed, as inc	ity considers contain an amendment that goes beyond dicated in item 4 of Box No. I and the Supplemental			
b. (sent to the Internation	onal Bureau only) a total of (indicate type and	number of electronic carrier(s))			
b (sent to the thier hade	mar Durioda Only) a count of (marcure type marc	, containing a sequence listing and/or tables			
related thereto, in comp Section 802 of the Adm	outer readable form only, as indicated in the inistrative Instructions).	Supplemental Box Relating to Sequence Listing (see			
4. This report contains indications r	relating to the following items:				
Box No. I Basis o	of the report				
Box No. II Priority	•				
	stablishment of opinion with regard to novelty	inventive step and industrial applicability			
I ==		, inventive step and industrial approximation			
<u> </u>	funity of invention	to nevelty, inventive step or industrial applicability			
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
Box No. VI Certain	n documents cited				
Box No. VII Certain	n defects in the international application				
Box No. VIII Certain	n observations on the international application	n			
Date of submission of the demand		ion of this report			
Date of submission of the demand		·			
Name and mailing address of the IPEA/E	P Authorized office	per			
	Talanhona Ma				
Facsimile No.	Telephone No.	· · · · · · · · · · · · · · · · · · ·			

Translation

International application No.
PCT/EP2004/002582

Box	No. I	Basis of the report			
1.	With indic	regard to the language, this report is based on the internation ated under this item.	al application in the language in which it	was filed, unless otherwise	
		This report is based on translations from the original language which is the language of a translation furnished for the purpo	ge into the following languageoses of:	,	
	international search (Rule 12.3 and 23.1(b))				
		publication of the international application (Rule 12.4)			
		international preliminary examination (Rule 55.2 and/o	or 55.3)		
2.	recei	regard to the <b>elements</b> of the international application, this is iving Office in response to an invitation under Article 14 are report):	report is based on (replacement sheets wh referred to in this report as "originally	nich have been furnished to the filed" and are not annexed to	
		the international application as originally filed/furnished			
	$\boxtimes$	the description:			
		pages 1-44		as originally filed/furnished	
		pages*	received by this Authority on		
		pages*	received by this Authority on		
	$\boxtimes$	the claims:			
		nos. 1-30		as originally filed/furnished	
		nos.*	as amended (together with ar		
		nos.*		•	
		nos.*			
	$\boxtimes$	the drawings:			
			received by this Authority on		
		sheets*	· · · · · · · · · · · · · · · · · · ·		
		a sequence listing and/or any related table(s) – see Supplem	ental Box Relating to Sequence Listing.		
3.		The amendments have resulted in the cancellation of:			
		the description, pages			
		the claims, nos.		<del></del>	
		the drawings, sheets/figs			
		the sequence listing (specify):			
		any table(s) related to sequence listing (specify):			
4.		This report has been established as if (some of) the amend they have been considered to go beyond the disclosure as file.	ments annexed to this report and listed b led, as indicated in the Supplemental Box	elow had not been made, since (Rule 70.2(c)).	
		the description, pages			
		the claims, nos.			
		the drawings, sheets/figs			
		the sequence listing (specify):			
		any table(s) related to sequence listing (specify):			
L.	If ite	em 4 applies, some or all of those sheets may be marked "sup	erseded."	<del>-</del>	

International application No. PCT/EP2004/002582

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
1.	Statement				-
	Novelty (N	1)	Claims	1-30	YES
			Claims		NO
	Inventive s	step (IS)	Claims		YES
			Claims	1-30	NO
	Industrial	applicability (IA)	Claims	1-30	YES
			Claims		NO
	Citations and	evalanations (Pula	70.7)		

- itations and explanations (Rule 70.7)
  - Reference to the following documents: 1.

D1: EP-A-O 486 290 (AMOCO CORP)

20 May 1992 (1992-05-20)

D2: DE 197 44 212 A (SCHERING AG)

15 April 1999 (1999-04-15).

- 2. The present application fails to satisfy the requirements of PCT Article 33(2) because the subject matter of claims 1-30 lacks novelty (PCT Article 33(2)).
- 3.1 Document D1 discloses (the references in brackets are to said document) a method for the production of a variety of sterols which can be regarded as intermediate and/or resultant products of ergosta-5,7-dienol, said method involving the cultivation of organisms which have a reduced  $\Delta 22$ -desaturase (erg5) activity and an increased HMG-CoA-reductase activity relative to the wild type (see claim 13).
- 3.2 Document D2 discloses a method for the production of a variety of sterols which can be regarded as

/...

PCT/EP2004/002582

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; Box No. V citations and explanations supporting such statement

> intermediate and/or resultant products of ergosta-5,7-dienol, said method involving the cultivation of organisms which have an increased HMG-CoA-reductase activity and increased squalene poxidase (erg1) activity relative to the wild type (see claim 2.a-iv)).

- The present application fails to satisfy the 4.1 requirements of PCT Article 33(1) because the subject matter of claims 1-30 does not involve an inventive step (PCT Article 33(3)).
- Document D1 is considered to be the prior art 4.2 closest to the subject matter of claim 1 and the subject matter of claim 1 therefore differs from D1 in that the method is implemented using organisms which, by comparison with the present claims, additionally display an increased activity of a further enzyme, which enzyme can be selected from the group comprising lanosterol-C14demethylase (erg11), squalene poxidase (erg1) and squalene synthetase (erg9).
- 4.3 The problem addressed by the present invention can consequently be regarded as that of providing an alternative method for producing ergosta-5-7dienol (and/or biosynthetic intermediate and/or resultant products thereof).

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- 4.4 The solution proposed in claims 1-10 and 15-18 of the present application cannot be considered inventive (PCT Article 33(3)) for the following reasons:
  - as stated in point 3.2 above, D2 discloses (see claim 2.a-iv)) a method for the production of ergosta-5-7-dienol and/or biosynthetic intermediate and/or resultant products thereof by means of an increased t-HMG and erg1 activity. A person skilled in the art could therefore arrive at the solution to the present problem by combining the disclosures of D1 and D2, without unreasonable experimental input.
- 4.5 Moreover, the problem cannot be considered to have been solved for the entire scope of protection claimed in claim 1: (i) it has not been shown that the problem has been solved for all intermediate and/or resultant products of ergosta-5,7-dienol. Tables 2 and 3 (data for S. cerevisiae GRFtHIura3ERG1erg5) show the decrease in the content of squalene (which can be considered to be an intermediate product of ergosta-5-7-dienol) by comparison with table 1 (data for S. cerevisiae GRFtHIura3) and table 3 (data for S. cerevisiae GRFtHIura3erg5); (ii) nor has it been shown that the aforementioned problem has been solved by an increase in lanosterol-C14-demethylase (erg11) or squalene synthetase (erg9) activity (in addition

/...

International application No.
PCT/EP2004/002582

Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
	to a reduction in erg5 activity and an increase in HMG reductase activity).
4.6	In consequence, claims 1-30 do not involve an inventive step (PCT Article 33(3)).

International application No.
PCT/EP2004/002582

Box	No. VI	Certain documents cited				
1. Certain published documents (Rule 70.10)						
		Application No. Patent No.	Publication date (day/month/year)	Filing o (day/mont)	late h/year)	Priority date (valid claim) (day/month/year)
		Talent 110.	( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (			
2.	Non-writter	n disclosures (Rule 70.9)				
		Kind of non-written disclosure	Date of non-w	ritten disclosure nth/year)	referring	of written disclosure to non-written disclosure (day/month/year)
Ì						
1						

International application No.
PCT/EP2004/002582

Supplemental	Box
--------------	-----

In case the space in any of the preceding boxes is not sufficient.

Continuation of:

#### Box VI

Document D4 (WO03/064650), cited in the search report, might be prejudicial to novelty in a later regional phase.